FDA Grand Rounds: Clinical Omics Biomarker Discovery and Validation in Precision Medicine

Why It Matters

Integrating multi‑omics biomarkers streamlines precision‑medicine diagnostics and informs regulatory pathways, ultimately enhancing patient safety and drug development efficiency.

Key Takeaways

• Omics integration accelerates biomarker discovery for drug safety.
• Early acylcarnitine rise signals acetaminophen‑induced mitochondrial dysfunction in liver.
• Multi‑omics workflow emphasizes sample handling, QC, and targeted analysis.
• Proteomic panels predict kidney recovery after dialysis‑dependent AKI.
• MicroRNA‑protein pairs enable severity assessment of respiratory diseases.

Summary

The FDA Grand Rounds session featured Dr. Richard Beger discussing clinical omics biomarker discovery and validation for precision‑medicine applications. He outlined the breadth of systems‑biology omics—genomics, transcriptomics, proteomics, metabolomics, lipidomics—and described a structured workflow that stresses early sample‑type decisions, rigorous quality control, and iterative bioinformatic modeling.

Key insights included the translation of non‑clinical metabolomics and microRNA data into clinical settings, illustrated by early elevation of long‑chain acylcarnitines as a mitochondrial toxicity signal in acetaminophen overdose. Additional case studies covered proteomic signatures that forecast kidney recovery after dialysis‑dependent acute kidney injury, baseline cardiotoxic proteomics predicting doxorubicin‑induced heart injury, and a novel method pairing microRNA‑protein markers to gauge respiratory disease severity.

Notable examples highlighted palmitoylcarnitine’s consistent rise across mouse, rat, and human studies, microRNA‑122 as a liver injury indicator, and the development of targeted LC‑MS assays that bridge open‑profiling discovery to clinical quantification. Dr. Beger emphasized the importance of multi‑omics integration to capture pre‑injury, injury, and recovery phases, enabling more nuanced phenotypic definitions.

The implications are clear: standardized, multi‑omics pipelines can accelerate biomarker qualification, support FDA regulatory frameworks, and empower clinicians to personalize therapy based on early, mechanistic signals rather than downstream clinical outcomes.

Original Description

Join us for an insightful FDA Grand Rounds presentation featuring Dr. Richard Beger, Branch Chief of the Omics Modeling, Imaging, and Chemistry Branch at NCTR's Division of Systems Biology. Dr. Beger presents cutting-edge research on clinical omics biomarker discovery and validation for precision medicine applications.

About the Speaker:

Dr. Richard Beger holds a doctorate in biophysics from Purdue University and completed postdoctoral training in nuclear magnetic resonance at Wesleyan University and Johns Hopkins University School of Medicine. He has been with NCTR since 1998 and has authored over 190 published manuscripts. Dr. Beger is a leader in metabolomics quality assurance and won the 2016 Society of Toxicology Translational Impact Award for developing translational approaches to improve drug safety and human health.

Topics Covered:

Systems biology and omics biomarker concepts

Translation of nonclinical metabolomics and microRNA biomarkers during acetaminophen toxicity

Discovery of proteomic biomarkers for predicting kidney recovery from dialysis-dependent AKI patients

Discovery and validation of baseline predictive cardiotoxic biomarkers in breast cancer patients receiving doxorubicin treatment

Method development for discovery and validation of microRNA-protein pairs associated with respiratory disease severity

Key Takeaways:

✓ Multi-omics approaches for biomarker discovery

✓ Translational biomarkers across species

✓ Predictive markers for drug-induced toxicity

✓ Integration of microRNA and proteomics data

✓ Quality control and validation strategies in omics research

Disclaimer: The views expressed in this presentation are those of the speaker and do not reflect the official position of the U.S. FDA.